KIF20A is a Prognostic Marker for Female Patients with Estrogen Receptor-Positive Breast Cancer and Receiving Tamoxifen as Adjuvant Endocrine Therapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Heindl A, Sestak I, Naidoo K, Cuzick J, Dowsett M, Yuan Y. Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after endocrine therapy of ER+ breast cancer. J Natl Cancer Inst. 2018;110(2). doi:10.1093/jnci/djx137
   PubMedGoogle Scholar
• Ohara AM, Naoi Y, Shimazu K, et al. PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. Breast Cancer Res Treat. 2019;173(3):533–543. doi:10.1007/s10549-018-5020-7
   PubMed Web of Science ®Google Scholar
• Emons G, Mustea A, Tempfer C. Tamoxifen and endometrial cancer: a janus-headed drug. Cancers. 2020;12(9):2535. doi:10.3390/cancers12092535
   PubMed Web of Science ®Google Scholar
• Cabling ML, Turner JW, Hurtado-de-Mendoza A, et al. Sentiment analysis of an online breast cancer support group: communicating about tamoxifen. Health Commun. 2018;33(9):1158–1165. doi:10.1080/10410236.2017.1339370
   PubMed Web of Science ®Google Scholar
• Heery M, Corbett P, Zelkowitz R. Precautions for patients taking tamoxifen. J Adv Pract Oncol. 2018;9(1):78–83.
   PubMedGoogle Scholar
• Shagufta and Ahmad I. Tamoxifen a pioneering drug: an update on the therapeutic potential of tamoxifen derivatives. Eur J Med Chem. 2018;143:515–531. doi:10.1016/j.ejmech.2017.11.056
   PubMed Web of Science ®Google Scholar
• Wu HT, Liu YE, Hsu KW, et al. MLL3 induced by luteolin causes apoptosis in tamoxifen-resistant breast cancer cells through H3K4 monomethylation and suppression of the PI3K/AKT/mTOR pathway. Am J Chin Med. 2020;48(5):1221–1241. doi:10.1142/S0192415X20500603
   PubMed Web of Science ®Google Scholar
• Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 2013;23(11):643–647. doi:10.1097/FPC.0b013e3283656bc1
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–816. doi:10.1016/S0140-6736(12)61963-1
   PubMed Web of Science ®Google Scholar
• Zhou J, Li W, Ming J, et al. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance. Anticancer Drugs. 2020;31(6):558–566. doi:10.1097/CAD.0000000000000943
   PubMed Web of Science ®Google Scholar
• Zhou L, Rueda M, Alkhateeb A. Classification of breast cancer nottingham prognostic index using high-dimensional embedding and residual neural network. Cancers. 2022;14(4):934. doi:10.3390/cancers14040934
   PubMed Web of Science ®Google Scholar
• Tabl AA, Alkhateeb A, ElMaraghy W, Rueda L, Ngom A. A machine learning approach for identifying gene biomarkers guiding the treatment of breast cancer. Front Genet. 2019;10:256. doi:10.3389/fgene.2019.00256
   PubMed Web of Science ®Google Scholar
• Bakre MM, Ramkumar C, Attuluri AK, et al. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. Cancer Med. 2019;8(4):1755–1764. doi:10.1002/cam4.2049
   PubMed Web of Science ®Google Scholar
• Loo CE, Rigter LS, Pengel KE, et al. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer. Breast Cancer Res. 2016;18(1):82. doi:10.1186/s13058-016-0742-0
   PubMedGoogle Scholar
• Wang K, Li J, Xiong YF, Zeng Z, Zhang X, Li HY. A potential prognostic long noncoding RNA signature to predict recurrence among ER-positive breast cancer patients treated with tamoxifen. Sci Rep. 2018;8(1):3179. doi:10.1038/s41598-018-21581-w
   PubMedGoogle Scholar
• Jin Z, Peng F, Zhang C, Tao S, Xu D, Zhu Z. Expression, regulating mechanism and therapeutic target of KIF20A in multiple cancer. Heliyon. 2023;9(2):e13195. doi:10.1016/j.heliyon.2023.e13195
   PubMed Web of Science ®Google Scholar
• Liu H, Chen C, Fehm T, Cheng Z, Neubauer H. Identifying mitotic kinesins as potential prognostic biomarkers in ovarian cancer using bioinformatic analyses. Diagnostics. 2022;12(2):470. doi:10.3390/diagnostics12020470
   Web of Science ®Google Scholar
• Taniuchi K, Nakagawa H, Nakamura T, et al. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005;65(1):105–112. doi:10.1158/0008-5472.105.65.1
   PubMed Web of Science ®Google Scholar
• Li X, Shu K, Wang Z, Ding D. Prognostic significance of KIF2A and KIF20A expression in human cancer: a systematic review and meta-analysis. Medicine. 2019;98(46):e18040. doi:10.1097/MD.0000000000018040
   PubMed Web of Science ®Google Scholar
• Nakamura M, Takano A, Thang PM, et al. Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. Int J Oncol. 2020;57(1):277–288. doi:10.3892/ijo.2020.5060
   PubMed Web of Science ®Google Scholar
• Zhang Q, Di J, Ji Z, et al. KIF20A predicts poor survival of patients and promotes colorectal cancer tumor progression through the JAK/STAT3 signaling pathway. Dis Markers. 2020;2020:2032679. doi:10.1155/2020/2032679
   PubMed Web of Science ®Google Scholar
• Aruga A, Takeshita N, Kotera Y, et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. J Transl Med. 2014;12:61. doi:10.1186/1479-5876-12-61
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Okada K, Omori T, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50(5):1655–1662. doi:10.3892/ijo.2017.3955
   PubMed Web of Science ®Google Scholar
• Miyazawa M, Katsuda M, Maguchi H, et al. Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. Int J Cancer. 2017;140(4):973–982. doi:10.1002/ijc.30510
   PubMed Web of Science ®Google Scholar
• Khongkow P, Gomes AR, Gong C, et al. Paclitaxel targets FOXM1 to regulate KIF20A in mitotic catastrophe and breast cancer paclitaxel resistance. Oncogene. 2016;35(8):990–1002. doi:10.1038/onc.2015.152
   PubMed Web of Science ®Google Scholar
• Yu H, Xu Z, Guo M, et al. FOXM1 modulates docetaxel resistance in prostate cancer by regulating KIF20A. Cancer Cell Int. 2020;20(1):545. doi:10.1186/s12935-020-01631-y
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang Y, Lin S, Liu Y, Li W. Suppressing the KIF20A/NUAK1/Nrf2/GPX4 signaling pathway induces ferroptosis and enhances the sensitivity of colorectal cancer to oxaliplatin. Aging. 2021;13(10):13515–13534. doi:10.18632/aging.202774
   PubMedGoogle Scholar
• Xiong M, Zhuang K, Luo Y, et al. KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway. Aging. 2019;11(24):11905–11921. doi:10.18632/aging.102505
   PubMedGoogle Scholar
• Győrffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101–4109. doi:10.1016/j.csbj.2021.07.014
   PubMed Web of Science ®Google Scholar
• Fekete JT, Győrffy B. ROCplot. org: validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3104 breast cancer patients. Int J Cancer. 2019;145(11):3140–3151. doi:10.1002/ijc.32369
   PubMed Web of Science ®Google Scholar
• Iwata H, Shien T. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020;50(3):225–229. doi:10.1093/jjco/hyz213
   PubMed Web of Science ®Google Scholar
• Sella T, Weiss A, Mittendorf EA, et al. Neoadjuvant endocrine therapy in clinical practice: a review. JAMA Oncol. 2021;7(11):1700–1708. doi:10.1001/jamaoncol.2021.2132
   PubMed Web of Science ®Google Scholar
• He H, Liang L, Huang J, et al. KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma. Front Pharmacol. 2022;13:1007429. doi:10.3389/fphar.2022.1007429
   PubMed Web of Science ®Google Scholar
• Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. doi:10.1186/s12943-022-01530-y
   PubMed Web of Science ®Google Scholar
• Xu Z, Tang J. RelB silencing to reverse tamoxifen resistance by regulating GPx4 and ferroptosis in breast cancer. J Clin Oncol. 2020;38(15_suppl):e12513. doi:10.1200/JCO.2020.38.15_suppl.e12513
   Web of Science ®Google Scholar
• Aogi K, Kadoya T, Sugawara Y, et al. Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer. Breast Cancer Res Treat. 2015;150(1):209–217. doi:10.1007/s10549-015-3303-9
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res. 2010;16(21):5222–5232. doi:10.1158/1078-0432.CCR-10-1282
   PubMed Web of Science ®Google Scholar
• Makower D, Lin J, Xue X, Sparano JA. Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. NPJ Breast Cancer. 2021;7(1):20. doi:10.1038/s41523-021-00231-x
   PubMed Web of Science ®Google Scholar
• Adachi Y, Oze I, Sawaki M, et al. Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer. Breast Cancer. 2021;28(5):1087–1095. doi:10.1007/s12282-021-01245-w
   PubMed Web of Science ®Google Scholar